下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

First Business Financial Services Inc. Has $480,000 Holdings in Pfizer Inc. (NYSE:PFE)
第一商业金融服务公司持有辉瑞48万美元的股份。

Financial News Live ·  {{timeTz}}

First Business Financial Services Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 4.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,267 shares of the biopharmaceutical company's stock after purchasing an additional 366 shares during the period. First Business Financial Services Inc.'s holdings in Pfizer were worth $480,000 at the end of the most recent quarter.

第一商业金融服务公司在最近提交给美国证券交易委员会的文件中说,该公司第一季度增持了辉瑞(纽约证券交易所代码:PFE-GET评级)的股票,增幅为4.1%。该机构投资者持有这家生物制药公司9267股票,在此期间又购买了366股。截至最近一个季度末,第一商业金融服务公司(First Business Financial Services Inc.)持有的辉瑞股份价值48万美元。

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Perfromance Wealth Partners LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $708,000. Total Clarity Wealth Management Inc. lifted its holdings in shares of Pfizer by 4.8% during the 4th quarter. Total Clarity Wealth Management Inc. now owns 17,542 shares of the biopharmaceutical company's stock worth $1,036,000 after acquiring an additional 802 shares during the period. Manchester Financial Inc. lifted its holdings in shares of Pfizer by 7.1% during the 4th quarter. Manchester Financial Inc. now owns 10,605 shares of the biopharmaceutical company's stock worth $626,000 after acquiring an additional 702 shares during the period. AHL Investment Management Inc. bought a new position in Pfizer in the 4th quarter valued at approximately $2,907,000. Finally, Kalos Management Inc. lifted its stake in Pfizer by 4.0% in the 4th quarter. Kalos Management Inc. now owns 17,105 shares of the biopharmaceutical company's stock valued at $813,000 after purchasing an additional 657 shares during the last quarter. Institutional investors and hedge funds own 66.50% of the company's stock.

其他机构投资者和对冲基金最近也对他们在该公司的头寸进行了调整。Performmance Wealth Partners LLC在第四季度购买了辉瑞公司价值约70.8万美元的新股。Total Clarity Wealth Management Inc.在第四季度增持了4.8%的辉瑞股票。Total Clarity Wealth Management Inc.目前持有这家生物制药公司17,542股股票,价值1,036,000美元,在此期间又购买了802股。曼彻斯特金融公司在第四季度增持了7.1%的辉瑞股票。曼彻斯特金融公司现在拥有10,605股这家生物制药公司的股票,价值626,000美元,在此期间又购买了702股。AHL投资管理公司在第四季度购买了辉瑞的一个新头寸,价值约290.7万美元。最后,Kalos Management Inc.在第四季度增持了辉瑞4.0%的股份。Kalos Management Inc.现在持有这家生物制药公司17,105股股票,价值813,000美元,此前该公司在上个季度又购买了657股。机构投资者和对冲基金持有该公司66.50%的股票。

Get
到达
Pfizer
辉瑞公司
alerts:
警报:

Pfizer Price Performance

辉瑞的性价比

PFE traded down $0.23 during trading on Wednesday, reaching $49.55. 534,736 shares of the company traded hands, compared to its average volume of 27,168,420. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. Pfizer Inc. has a 12-month low of $40.94 and a 12-month high of $61.71. The firm has a fifty day simple moving average of $50.94 and a 200 day simple moving average of $51.03. The company has a market cap of $278.02 billion, a P/E ratio of 9.69, a PEG ratio of 0.60 and a beta of 0.67.

在周三的交易中,PFE交易价格下跌0.23美元,至49.55美元。该公司有534,736股易手,而其平均成交量为27,168,420股。该公司的负债权益比率为0.43,速动比率为1.13,流动比率为1.39。辉瑞公司股价跌至40.94美元的12个月低点和61.71美元的12个月高位。该公司的50日简单移动均线为50.94美元,200日简单移动均线为51.03美元。该公司市值为2780.2亿美元,市盈率为9.69倍,聚乙二醇率为0.60倍,贝塔系数为0.67倍。

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.95 by $0.09. Pfizer had a net margin of 28.92% and a return on equity of 44.38%. The business had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. During the same period last year, the firm posted $1.07 EPS. The company's revenue was up 46.8% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 6.54 EPS for the current year.
辉瑞(NYSE:PFE-GET Rating)上一次公布季度收益数据是在7月28日星期四。这家生物制药公司公布本季度每股收益(EPS)为2.04美元,超出分析师普遍预期的1.95美元,超出0.09美元。辉瑞的净利润率为28.92%,股本回报率为44.38%。该业务本季度营收为277.4亿美元,而分析师预期为262亿美元。去年同期,该公司公布的每股收益为1.07美元。该公司的收入同比增长了46.8%。股票分析师平均预测辉瑞公司本年度每股收益为6.54欧元。

Pfizer Announces Dividend

辉瑞宣布分红

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Wednesday, June 29th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 3.23%. The ex-dividend date of this dividend is Thursday, July 28th. Pfizer's dividend payout ratio (DPR) is currently 31.31%.

该公司最近还披露了季度股息,将于9月6日(星期二)支付。6月29日(星期三)登记在册的股东将获得每股0.40美元的股息。这意味着年化股息为1.60美元,收益率为3.23%。本次股息除息日期为7月28日(星期四)。辉瑞的股息支付率(DPR)目前为31.31%。

Insider Buying and Selling at Pfizer

辉瑞的内幕买卖

In related news, SVP Jennifer B. Damico sold 4,000 shares of the business's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total value of $202,000.00. Following the sale, the senior vice president now owns 15,064 shares in the company, valued at $760,732. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Jennifer B. Damico sold 4,000 shares of the business's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total value of $202,000.00. Following the sale, the senior vice president now owns 15,064 shares in the company, valued at $760,732. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jennifer B. Damico sold 4,218 shares of the business's stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total transaction of $227,603.28. Following the completion of the sale, the senior vice president now owns 10,846 shares in the company, valued at approximately $585,250.16. The disclosure for this sale can be found here. Insiders sold a total of 41,126 shares of company stock valued at $2,075,003 in the last three months. 0.05% of the stock is currently owned by corporate insiders.

在相关新闻中,高级副总裁詹妮弗·B·达米科在5月16日星期一的一次交易中出售了4000股该公司的股票。这些股票的平均价格为50.50美元,总价值为202,000.00美元。出售后,高级副总裁现在拥有该公司15,064股,价值760,732美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,这份文件可以在美国证券交易委员会的网站上找到。在相关新闻中,高级副总裁詹妮弗·B·达米科在5月16日星期一的一次交易中出售了4000股该公司的股票。这些股票的平均价格为50.50美元,总价值为202,000.00美元。出售后,高级副总裁现在拥有该公司15,064股,价值760,732美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,这份文件可以在美国证券交易委员会的网站上找到。此外,高级副总裁詹妮弗·B·达米科在6月7日星期二的一次交易中出售了4218股该公司的股票。该股以53.96美元的平均价格出售,总成交金额为227,603.28美元。出售完成后,高级副总裁现在拥有该公司10,846股股份,价值约585,250.16美元。此次拍卖的披露信息可在此处找到。在过去的三个月里,内部人士总共出售了41,126股公司股票,价值2,075,003美元。公司内部人士目前持有该公司0.05%的股份。

Analysts Set New Price Targets

分析师设定新的价格目标

Several research firms have recently issued reports on PFE. Barclays raised their price target on shares of Pfizer to $52.00 in a research note on Tuesday. SVB Leerink dropped their price target on shares of Pfizer from $55.00 to $53.00 and set a "market perform" rating for the company in a research note on Friday, July 29th. Morgan Stanley dropped their price target on shares of Pfizer from $52.00 to $49.00 and set an "equal weight" rating for the company in a research note on Friday, July 8th. Wells Fargo & Company dropped their price target on shares of Pfizer from $60.00 to $55.00 in a research note on Wednesday, May 4th. Finally, The Goldman Sachs Group set a $50.00 price target on shares of Pfizer in a research note on Friday, July 29th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $57.50.

几家研究公司最近发布了关于PFE的报告。巴克莱周二在一份研究报告中将辉瑞股票的目标价上调至52.00美元。7月29日,SVB Leerink在一份研究报告中将辉瑞股票的目标价从55.00美元下调至53.00美元,并为该公司设定了“市场表现”评级。摩根士丹利在7月8日星期五的一份研究报告中将辉瑞股票的目标价从52.00美元下调至49.00美元,并为该公司设定了“同等权重”的评级。富国银行在5月4日星期三的一份研究报告中将辉瑞股票的目标价从60.00美元下调至55.00美元。最后,高盛在7月29日星期五的一份研究报告中为辉瑞股票设定了50美元的目标价。9位分析师对该股的评级为持有,10位分析师给出了买入评级,一位分析师给出了强烈的买入评级。根据MarketBeat.com,该股目前的普遍评级为“适度买入”,平均目标价为57.50美元.

Pfizer Company Profile

辉瑞公司简介

(Get Rating)

(获取评级)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

辉瑞在全球发现、开发、制造、营销、分销和销售生物制药产品。该公司在不同的治疗领域提供药物和疫苗,包括Premarin系列和Eiquis品牌的心血管代谢和妇女健康;Ibrance、Xtandi、Sutent、Inlyta、Retacritt、Lorbrena和Braftovi品牌的生物制品、小分子、免疫疗法和生物仿制药;舒必乐、Medrol、Zavicefta、Zithromax、Vfend、Panzyga和Paxlovid品牌的无菌注射和抗感染药物以及口服新冠肺炎治疗。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on Pfizer (PFE)
  • The How and Why of Investing in Gold Stocks
  • A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
  • Workhorse Group Is Ready To Get Back On The Horse
  • Are 3M, Honeywell, GE Buys After Quarterly Reports?
  • CVS and Walgreens Show Why Investment Objectives Matter
  • 免费获取StockNews.com关于辉瑞的研究报告
  • 投资黄金股票的方式和原因
  • DraftKings,Inc.的圆底开始逆转
  • 工作马集团准备重返赛马
  • 3M、霍尼韦尔、通用电气在季度报告后收购吗?
  • CVS和Walgreens展示为什么投资目标很重要

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

接受辉瑞日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对辉瑞及相关公司评级的每日简明摘要。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。

回到顶部